No Cover Image

Journal article 816 views 114 downloads

3D Bioprinting and the Future of Surgery

Thomas Jovic, Emman Thomson, Zita Jessop Orcid Logo, Iain Whitaker

Frontiers in Surgery, Volume: 7

Swansea University Authors: Thomas Jovic, Emman Thomson, Zita Jessop Orcid Logo, Iain Whitaker

  • 55848.pdf

    PDF | Version of Record

    © 2020 Jovic, Combellack, Jessop and Whitaker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).

    Download (1.1MB)

Check full text

DOI (Published version): 10.3389/fsurg.2020.609836

Abstract

Introduction: The disciplines of 3D bioprinting and surgery have witnessed incremental transformations over the last century. 3D bioprinting is a convergence of biology and engineering technologies, mirroring the clinical need to produce viable biological tissue through advancements in printing, reg...

Full description

Published in: Frontiers in Surgery
ISSN: 2296-875X
Published: Frontiers Media SA 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa55848
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2020-12-07T17:12:45Z
last_indexed 2021-01-26T04:19:56Z
id cronfa55848
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2021-01-25T13:49:51.6321079</datestamp><bib-version>v2</bib-version><id>55848</id><entry>2020-12-07</entry><title>3D Bioprinting and the Future of Surgery</title><swanseaauthors><author><sid>7d95ed2bceb18fc0fdfd4048277c6eed</sid><firstname>Thomas</firstname><surname>Jovic</surname><name>Thomas Jovic</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>dc9e7718f6f8bb11d3df1d0cd8245318</sid><firstname>Emman</firstname><surname>Thomson</surname><name>Emman Thomson</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>0184f610b62d649a59dad304e48ea03b</sid><ORCID>0000-0003-2886-9165</ORCID><firstname>Zita</firstname><surname>Jessop</surname><name>Zita Jessop</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>830074c59291938a55b480dcbee4697e</sid><ORCID/><firstname>Iain</firstname><surname>Whitaker</surname><name>Iain Whitaker</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-12-07</date><deptcode>BMS</deptcode><abstract>Introduction: The disciplines of 3D bioprinting and surgery have witnessed incremental transformations over the last century. 3D bioprinting is a convergence of biology and engineering technologies, mirroring the clinical need to produce viable biological tissue through advancements in printing, regenerative medicine and materials science. To outline the current and future challenges of 3D bioprinting technology in surgery. Methods: A comprehensive literature search was undertaken using the MEDLINE, EMBASE and Google Scholar databases between 2000 and 2019. A narrative synthesis of the resulting literature was produced to discuss 3D bioprinting, current and future challenges, the role in personalized medicine and transplantation surgery and the global 3D bioprinting market. Results: The next 20 years will see the advent of bioprinted implants for surgical use, however the path to clinical incorporation will be fraught with an array of ethical, regulatory and technical challenges of which each must be surmounted. Previous clinical cases where regulatory processes have been bypassed have led to poor outcomes and controversy. Speculated roles of 3D bioprinting in surgery include the production of de novo organs for transplantation and use of autologous cellular material for personalized medicine. The promise of these technologies has sparked an industrial revolution, leading to an exponential growth of the 3D bioprinting market worth billions of dollars. Conclusion: Effective translation requires the input of scientists, engineers, clinicians, and regulatory bodies: there is a need for a collaborative effort to translate this impactful technology into a real-world healthcare setting and potentially transform the future of surgery.</abstract><type>Journal Article</type><journal>Frontiers in Surgery</journal><volume>7</volume><journalNumber/><paginationStart/><paginationEnd/><publisher>Frontiers Media SA</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2296-875X</issnElectronic><keywords>3D printing, transplantation, biotechnology, bioprinting, reconstruction</keywords><publishedDay>27</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-11-27</publishedDate><doi>10.3389/fsurg.2020.609836</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>UKRI, MR/N002431/1</funders><lastEdited>2021-01-25T13:49:51.6321079</lastEdited><Created>2020-12-07T17:09:49.0341634</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Thomas</firstname><surname>Jovic</surname><order>1</order></author><author><firstname>Emman</firstname><surname>Thomson</surname><order>2</order></author><author><firstname>Zita</firstname><surname>Jessop</surname><orcid>0000-0003-2886-9165</orcid><order>3</order></author><author><firstname>Iain</firstname><surname>Whitaker</surname><orcid/><order>4</order></author></authors><documents><document><filename>55848__18839__b5070ab0e48140b3bfb33592a007fdde.pdf</filename><originalFilename>55848.pdf</originalFilename><uploaded>2020-12-07T17:13:29.0696934</uploaded><type>Output</type><contentLength>1150097</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2020 Jovic, Combellack, Jessop and Whitaker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2021-01-25T13:49:51.6321079 v2 55848 2020-12-07 3D Bioprinting and the Future of Surgery 7d95ed2bceb18fc0fdfd4048277c6eed Thomas Jovic Thomas Jovic true false dc9e7718f6f8bb11d3df1d0cd8245318 Emman Thomson Emman Thomson true false 0184f610b62d649a59dad304e48ea03b 0000-0003-2886-9165 Zita Jessop Zita Jessop true false 830074c59291938a55b480dcbee4697e Iain Whitaker Iain Whitaker true false 2020-12-07 BMS Introduction: The disciplines of 3D bioprinting and surgery have witnessed incremental transformations over the last century. 3D bioprinting is a convergence of biology and engineering technologies, mirroring the clinical need to produce viable biological tissue through advancements in printing, regenerative medicine and materials science. To outline the current and future challenges of 3D bioprinting technology in surgery. Methods: A comprehensive literature search was undertaken using the MEDLINE, EMBASE and Google Scholar databases between 2000 and 2019. A narrative synthesis of the resulting literature was produced to discuss 3D bioprinting, current and future challenges, the role in personalized medicine and transplantation surgery and the global 3D bioprinting market. Results: The next 20 years will see the advent of bioprinted implants for surgical use, however the path to clinical incorporation will be fraught with an array of ethical, regulatory and technical challenges of which each must be surmounted. Previous clinical cases where regulatory processes have been bypassed have led to poor outcomes and controversy. Speculated roles of 3D bioprinting in surgery include the production of de novo organs for transplantation and use of autologous cellular material for personalized medicine. The promise of these technologies has sparked an industrial revolution, leading to an exponential growth of the 3D bioprinting market worth billions of dollars. Conclusion: Effective translation requires the input of scientists, engineers, clinicians, and regulatory bodies: there is a need for a collaborative effort to translate this impactful technology into a real-world healthcare setting and potentially transform the future of surgery. Journal Article Frontiers in Surgery 7 Frontiers Media SA 2296-875X 3D printing, transplantation, biotechnology, bioprinting, reconstruction 27 11 2020 2020-11-27 10.3389/fsurg.2020.609836 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University UKRI, MR/N002431/1 2021-01-25T13:49:51.6321079 2020-12-07T17:09:49.0341634 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Thomas Jovic 1 Emman Thomson 2 Zita Jessop 0000-0003-2886-9165 3 Iain Whitaker 4 55848__18839__b5070ab0e48140b3bfb33592a007fdde.pdf 55848.pdf 2020-12-07T17:13:29.0696934 Output 1150097 application/pdf Version of Record true © 2020 Jovic, Combellack, Jessop and Whitaker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). true eng http://creativecommons.org/licenses/by/4.0/
title 3D Bioprinting and the Future of Surgery
spellingShingle 3D Bioprinting and the Future of Surgery
Thomas Jovic
Emman Thomson
Zita Jessop
Iain Whitaker
title_short 3D Bioprinting and the Future of Surgery
title_full 3D Bioprinting and the Future of Surgery
title_fullStr 3D Bioprinting and the Future of Surgery
title_full_unstemmed 3D Bioprinting and the Future of Surgery
title_sort 3D Bioprinting and the Future of Surgery
author_id_str_mv 7d95ed2bceb18fc0fdfd4048277c6eed
dc9e7718f6f8bb11d3df1d0cd8245318
0184f610b62d649a59dad304e48ea03b
830074c59291938a55b480dcbee4697e
author_id_fullname_str_mv 7d95ed2bceb18fc0fdfd4048277c6eed_***_Thomas Jovic
dc9e7718f6f8bb11d3df1d0cd8245318_***_Emman Thomson
0184f610b62d649a59dad304e48ea03b_***_Zita Jessop
830074c59291938a55b480dcbee4697e_***_Iain Whitaker
author Thomas Jovic
Emman Thomson
Zita Jessop
Iain Whitaker
author2 Thomas Jovic
Emman Thomson
Zita Jessop
Iain Whitaker
format Journal article
container_title Frontiers in Surgery
container_volume 7
publishDate 2020
institution Swansea University
issn 2296-875X
doi_str_mv 10.3389/fsurg.2020.609836
publisher Frontiers Media SA
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Introduction: The disciplines of 3D bioprinting and surgery have witnessed incremental transformations over the last century. 3D bioprinting is a convergence of biology and engineering technologies, mirroring the clinical need to produce viable biological tissue through advancements in printing, regenerative medicine and materials science. To outline the current and future challenges of 3D bioprinting technology in surgery. Methods: A comprehensive literature search was undertaken using the MEDLINE, EMBASE and Google Scholar databases between 2000 and 2019. A narrative synthesis of the resulting literature was produced to discuss 3D bioprinting, current and future challenges, the role in personalized medicine and transplantation surgery and the global 3D bioprinting market. Results: The next 20 years will see the advent of bioprinted implants for surgical use, however the path to clinical incorporation will be fraught with an array of ethical, regulatory and technical challenges of which each must be surmounted. Previous clinical cases where regulatory processes have been bypassed have led to poor outcomes and controversy. Speculated roles of 3D bioprinting in surgery include the production of de novo organs for transplantation and use of autologous cellular material for personalized medicine. The promise of these technologies has sparked an industrial revolution, leading to an exponential growth of the 3D bioprinting market worth billions of dollars. Conclusion: Effective translation requires the input of scientists, engineers, clinicians, and regulatory bodies: there is a need for a collaborative effort to translate this impactful technology into a real-world healthcare setting and potentially transform the future of surgery.
published_date 2020-11-27T04:10:21Z
_version_ 1763753718413524992
score 11.012678

Similar Items